Brilinta Description

Concise Prescribing Info Bahasa Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Description

Each tablet contains 90 mg of ticagrelor.
Each tablet contains 60 mg of ticagrelor.
BRILINTA contains ticagrelor, a cyclopentyltriazolopyrimidine, inhibitor of platelet activation and aggregation mediated by the P2Y12 ADP-receptor. Chemically, it is (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5-(2hydroxyethoxy)cyclopentane-1,2-diol. The empirical formula of ticagrelor is C₂₃H₂₈F₂N₆O₄S and its molecular weight is 522.57.
Ticagrelor is a crystalline powder with an aqueous solubility of approximately 10 μg/mL at room temperature.
Excipients/Inactive Ingredients: 90 mg film coated tablet: Core: Mannitol (E421), Dibasic calcium phosphate, Magnesium stearate, Sodium starch glycolate, Hydroxypropyl cellulose.
Coating: Talc, Titanium dioxide (E171), Ferric oxide yellow (E172), Polyethylene glycol 400, Hypromellose.
60 mg film coated tablet: Core: Mannitol (E421), Dibasic calcium phosphate, Magnesium stearate, Sodium starch glycolate, Hydroxypropyl cellulose.
Coating: Titanium dioxide (E171), Ferric oxide black (E172), Ferric oxide red (E172), Polyethylene glycol 400, Hypromellose.

Manufacturer:

AstraZeneca